Suheung Co., Ltd. (008490.KS)
KRW 14260.0
(-0.28%)
KRW 14260.0
(-0.28%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 594.56 Billion KRW | -6.36% |
| 2022 | 634.96 Billion KRW | 6.41% |
| 2021 | 596.73 Billion KRW | 7.91% |
| 2020 | 553.01 Billion KRW | 20.03% |
| 2019 | 460.72 Billion KRW | 17.09% |
| 2018 | 393.47 Billion KRW | 12.42% |
| 2017 | 350 Billion KRW | 2.83% |
| 2016 | 340.36 Billion KRW | 11.92% |
| 2015 | 304.12 Billion KRW | 4.47% |
| 2014 | 291.11 Billion KRW | 7.82% |
| 2013 | 269.98 Billion KRW | 30.41% |
| 2012 | 207.02 Billion KRW | 10.2% |
| 2011 | 187.86 Billion KRW | -5.85% |
| 2010 | 199.53 Billion KRW | 36.53% |
| 2009 | 146.14 Billion KRW | 20.34% |
| 2008 | 121.44 Billion KRW | 28.95% |
| 2007 | 94.18 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 172.76 Billion KRW | 4.49% |
| 2024 Q1 | 165.34 Billion KRW | 24.12% |
| 2023 Q4 | 133.2 Billion KRW | -12.54% |
| 2023 FY | 594.56 Billion KRW | -6.36% |
| 2023 Q1 | 155.28 Billion KRW | 18.03% |
| 2023 Q2 | 153.77 Billion KRW | -0.98% |
| 2023 Q3 | 152.3 Billion KRW | -0.95% |
| 2022 Q2 | 171.93 Billion KRW | 4.93% |
| 2022 Q3 | 167.61 Billion KRW | -2.51% |
| 2022 Q4 | 131.56 Billion KRW | -21.51% |
| 2022 Q1 | 163.85 Billion KRW | 22.83% |
| 2022 FY | 634.96 Billion KRW | 6.41% |
| 2021 Q3 | 144.76 Billion KRW | -6.44% |
| 2021 Q4 | 133.4 Billion KRW | -7.85% |
| 2021 FY | 596.73 Billion KRW | 7.91% |
| 2021 Q1 | 163.83 Billion KRW | 34.88% |
| 2021 Q2 | 154.72 Billion KRW | -5.56% |
| 2020 Q1 | 143.03 Billion KRW | 24.63% |
| 2020 FY | 553.01 Billion KRW | 20.03% |
| 2020 Q4 | 121.47 Billion KRW | -16.08% |
| 2020 Q3 | 144.74 Billion KRW | 0.68% |
| 2020 Q2 | 143.76 Billion KRW | 0.51% |
| 2019 FY | 460.72 Billion KRW | 17.09% |
| 2019 Q4 | 114.76 Billion KRW | 1.76% |
| 2019 Q3 | 112.77 Billion KRW | -2.28% |
| 2019 Q1 | 117.79 Billion KRW | 23.3% |
| 2019 Q2 | 115.4 Billion KRW | -2.03% |
| 2018 Q2 | 104.09 Billion KRW | 5.08% |
| 2018 Q3 | 94.78 Billion KRW | -8.95% |
| 2018 Q4 | 95.53 Billion KRW | 0.79% |
| 2018 FY | 393.47 Billion KRW | 12.42% |
| 2018 Q1 | 99.06 Billion KRW | 25.45% |
| 2017 FY | 350 Billion KRW | 2.83% |
| 2017 Q4 | 78.96 Billion KRW | -11.72% |
| 2017 Q3 | 89.44 Billion KRW | -2.32% |
| 2017 Q2 | 91.56 Billion KRW | 1.71% |
| 2017 Q1 | 90.02 Billion KRW | 10.75% |
| 2016 FY | 340.36 Billion KRW | 11.92% |
| 2016 Q4 | 81.29 Billion KRW | -9.82% |
| 2016 Q3 | 90.14 Billion KRW | 2.14% |
| 2016 Q2 | 88.25 Billion KRW | 9.41% |
| 2016 Q1 | 80.66 Billion KRW | 16.56% |
| 2015 Q3 | 75.9 Billion KRW | -6.65% |
| 2015 FY | 304.12 Billion KRW | 4.47% |
| 2015 Q1 | 77.69 Billion KRW | 16.0% |
| 2015 Q2 | 81.31 Billion KRW | 4.66% |
| 2015 Q4 | 69.2 Billion KRW | -8.82% |
| 2014 FY | 291.11 Billion KRW | 7.82% |
| 2014 Q4 | 66.97 Billion KRW | -10.86% |
| 2014 Q3 | 75.14 Billion KRW | 0.77% |
| 2014 Q2 | 74.56 Billion KRW | 0.19% |
| 2014 Q1 | 74.42 Billion KRW | 10.47% |
| 2013 Q1 | 63.86 Billion KRW | 25.54% |
| 2013 Q2 | 69.35 Billion KRW | 8.59% |
| 2013 FY | 269.98 Billion KRW | 30.41% |
| 2013 Q4 | 67.37 Billion KRW | -2.92% |
| 2013 Q3 | 69.4 Billion KRW | 0.07% |
| 2012 Q3 | 52.96 Billion KRW | -0.76% |
| 2012 Q2 | 53.36 Billion KRW | 46.48% |
| 2012 Q4 | 50.87 Billion KRW | -3.94% |
| 2012 FY | 207.02 Billion KRW | 10.2% |
| 2012 Q1 | 36.43 Billion KRW | 0.0% |
| 2011 Q2 | 36.69 Billion KRW | 1.04% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 187.86 Billion KRW | -5.85% |
| 2011 Q1 | 36.31 Billion KRW | 0.0% |
| 2011 Q3 | 33.72 Billion KRW | -8.07% |
| 2010 Q2 | 35.38 Billion KRW | 36.21% |
| 2010 FY | 199.53 Billion KRW | 36.53% |
| 2010 Q1 | 25.97 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q3 | 31.16 Billion KRW | -11.94% |
| 2009 Q2 | 29.44 Billion KRW | 16.69% |
| 2009 Q1 | 25.23 Billion KRW | 0.0% |
| 2009 FY | 146.14 Billion KRW | 20.34% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 26.27 Billion KRW | -10.76% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 121.44 Billion KRW | 28.95% |
| 2008 Q2 | 26.44 Billion KRW | 19.03% |
| 2008 Q3 | 24.72 Billion KRW | -6.49% |
| 2008 Q1 | 22.21 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 94.18 Billion KRW | 0.0% |
| 2007 Q3 | 20.99 Billion KRW | -2.88% |
| 2007 Q1 | 19.57 Billion KRW | 0.0% |
| 2007 Q2 | 21.61 Billion KRW | 10.44% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -333.328% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 47.477% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -60.461% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 1.03% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 6.873% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -164.892% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -339.208% |
| Yuhan Corporation | 1858.98 Billion KRW | 68.017% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 10.454% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1044.388% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -340.714% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -571.118% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -250.638% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -103.529% |
| CKD Bio Corp. | 160.35 Billion KRW | -270.787% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -333.328% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -293.568% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -580.566% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 20.568% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -196.944% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -228.921% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -153.112% |
| HANDOK Inc. | 522.74 Billion KRW | -13.74% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -333.328% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 60.74% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 56.769% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 20.568% |
| Yuhan Corporation | 1858.98 Billion KRW | 68.017% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 25.185% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 60.12% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 64.384% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 20.568% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 32.419% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -661.746% |
| JW Holdings Corporation | 928.07 Billion KRW | 35.935% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -202.816% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 18.148% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -196.944% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -12.831% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -113.15% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -158.066% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -64.651% |
| Boryung Corporation | 859.62 Billion KRW | 30.834% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -372.148% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -60.461% |
| JW Lifescience Corporation | 206.86 Billion KRW | -187.424% |